Brief: Allena Pharmaceuticals Completes Enrollment In Pivotal Phase 3 Urirox-1 Trial Evaluating Reloxaliase In Patients With Enteric Hyperoxaluria
16/09/2019 13:47
Sept 16 (Reuters) - Allena Pharmaceuticals Inc ALNA.O :
* ALLENA PHARMACEUTICALS COMPLETES ENROLLMENT IN PIVOTAL
PHASE 3
URIROX-1 TRIAL EVALUATING RELOXALIASE IN PATIENTS WITH ENTERIC
HYPEROXALURIA
* ALLENA PHARMACEUTICALS INC - EXPECTS TO REPORT TOPLINE
DATA FROM
TRIAL IN Q4 OF 2019
Source text for Eikon: ID:nGNXW4whs
Further company coverage: ALNA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allena Pharmaceuticals
See all newsBrief: Allena Pharmaceuticals Inc - On September 6, Received Notice From Nasdaq That Its Shares Will Be Suspended At Open Of Business On September 8, 2022
U.S. STOCKS ON THE MOVE-Relmada, Entera Bio, Eli Lilly
U.S. STOCKS ON THE MOVE-ChannelAdvisor, HyreCar, ADT, miners
U.S. STOCKS ON THE MOVE-Timken, Bed Bath & Beyond, HyreCar, chip stocks
Allena down on bankruptcy filing